Armata Pharmaceuticals, Inc. (ARMP)
USD 1.13
(-9.6%)
USD 1.13
(-9.6%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -69.04 Million USD | -87.17% |
| 2022 | -36.88 Million USD | -58.87% |
| 2021 | -23.21 Million USD | -1.77% |
| 2020 | -22.81 Million USD | -19.92% |
| 2019 | -19.02 Million USD | -57.1% |
| 2018 | -12.11 Million USD | 5.67% |
| 2017 | -12.83 Million USD | 31.85% |
| 2016 | -18.83 Million USD | -3550.78% |
| 2015 | -516 Thousand USD | -102.23% |
| 2014 | 23.1 Million USD | 139.56% |
| 2013 | -58.41 Million USD | -5162.25% |
| 2012 | -1.11 Million USD | 0.0% |
| 2008 | -20.72 Million USD | -28.48% |
| 2007 | -16.12 Million USD | 52.55% |
| 2006 | -33.99 Million USD | -77.05% |
| 2005 | -19.19 Million USD | -34.66% |
| 2004 | -14.25 Million USD | 3.88% |
| 2003 | -14.83 Million USD | 37.59% |
| 2002 | -23.76 Million USD | 12.52% |
| 2001 | -27.17 Million USD | 42.99% |
| 2000 | -47.65 Million USD | -78.49% |
| 1999 | -26.7 Million USD | -206.9% |
| 1998 | -8.7 Million USD | 38.73% |
| 1997 | -14.2 Million USD | 45.38% |
| 1996 | -26 Million USD | -162.63% |
| 1995 | -9.9 Million USD | -17.86% |
| 1994 | -8.4 Million USD | -64.71% |
| 1993 | -5.1 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -25.02 Million USD | -26.07% |
| 2024 Q2 | 8.98 Million USD | 135.91% |
| 2023 FY | -69.04 Million USD | -87.17% |
| 2023 Q1 | -17.63 Million USD | -71.19% |
| 2023 Q2 | -3.54 Million USD | 79.89% |
| 2023 Q4 | -19.84 Million USD | 36.31% |
| 2023 Q3 | -31.16 Million USD | -778.52% |
| 2022 Q2 | -9.21 Million USD | -4.98% |
| 2022 FY | -36.88 Million USD | -58.87% |
| 2022 Q1 | -8.77 Million USD | -45.08% |
| 2022 Q4 | -10.3 Million USD | -19.71% |
| 2022 Q3 | -8.6 Million USD | 6.57% |
| 2021 Q3 | -5.41 Million USD | 12.51% |
| 2021 Q4 | -6.04 Million USD | -11.59% |
| 2021 Q1 | -5.49 Million USD | 17.04% |
| 2021 Q2 | -6.19 Million USD | -12.72% |
| 2021 FY | -23.21 Million USD | -1.77% |
| 2020 Q2 | -4.71 Million USD | 7.25% |
| 2020 Q3 | -5.76 Million USD | -22.48% |
| 2020 Q4 | -6.62 Million USD | -14.82% |
| 2020 FY | -22.81 Million USD | -19.92% |
| 2020 Q1 | -5.07 Million USD | -10.73% |
| 2019 Q1 | -3.61 Million USD | 16.27% |
| 2019 FY | -19.02 Million USD | -57.1% |
| 2019 Q2 | -4.19 Million USD | -16.09% |
| 2019 Q3 | -6.95 Million USD | -65.63% |
| 2019 Q4 | -4.58 Million USD | 34.06% |
| 2018 Q2 | -3.05 Million USD | 2.68% |
| 2018 FY | -12.11 Million USD | 5.67% |
| 2018 Q4 | -4.32 Million USD | -168.99% |
| 2018 Q3 | -1.6 Million USD | 47.34% |
| 2018 Q1 | -3.13 Million USD | -33.25% |
| 2017 Q2 | -6.46 Million USD | -99.04% |
| 2017 Q4 | -2.35 Million USD | -201.93% |
| 2017 Q1 | -3.24 Million USD | 65.83% |
| 2017 FY | -12.83 Million USD | 31.85% |
| 2017 Q3 | -779 Thousand USD | 87.94% |
| 2016 Q1 | -3.11 Million USD | -39.49% |
| 2016 FY | -18.83 Million USD | -3550.78% |
| 2016 Q3 | -2.37 Million USD | 38.33% |
| 2016 Q4 | -9.5 Million USD | -300.0% |
| 2016 Q2 | -3.85 Million USD | -23.75% |
| 2015 Q3 | 5.43 Million USD | -49.49% |
| 2015 Q2 | 10.76 Million USD | 174.3% |
| 2015 Q1 | -14.49 Million USD | -4276.66% |
| 2015 FY | -516 Thousand USD | -102.23% |
| 2015 Q4 | -2.23 Million USD | -141.02% |
| 2014 Q2 | 15.4 Million USD | 251.84% |
| 2014 Q3 | 19.38 Million USD | 25.87% |
| 2014 Q4 | 347 Thousand USD | -98.21% |
| 2014 FY | 23.1 Million USD | 139.56% |
| 2014 Q1 | -10.14 Million USD | -253.0% |
| 2013 Q3 | -48.75 Million USD | -232.94% |
| 2013 Q4 | 6.63 Million USD | 113.6% |
| 2013 Q2 | -14.64 Million USD | -790.15% |
| 2013 Q1 | -1.64 Million USD | 0.0% |
| 2013 FY | -58.41 Million USD | -5162.25% |
| 2012 FY | -1.11 Million USD | 0.0% |
| 2009 Q1 | -1.78 Million USD | 83.56% |
| 2009 Q2 | 7.31 Million USD | 509.75% |
| 2009 Q3 | 671 Thousand USD | -90.82% |
| 2008 Q3 | -2.66 Million USD | 29.92% |
| 2008 FY | -20.72 Million USD | -28.48% |
| 2008 Q4 | -10.84 Million USD | -307.7% |
| 2008 Q1 | -3.41 Million USD | 32.72% |
| 2008 Q2 | -3.79 Million USD | -11.25% |
| 2007 Q1 | -3.83 Million USD | -574.75% |
| 2007 Q2 | -4.18 Million USD | -9.15% |
| 2007 Q3 | -3.03 Million USD | 27.61% |
| 2007 Q4 | -5.07 Million USD | -67.37% |
| 2007 FY | -16.12 Million USD | 52.55% |
| 2006 Q1 | -3.73 Million USD | -5.16% |
| 2006 Q2 | -27.87 Million USD | -646.95% |
| 2006 Q4 | 808 Thousand USD | 125.33% |
| 2006 Q3 | -3.19 Million USD | 88.56% |
| 2006 FY | -33.99 Million USD | -77.05% |
| 2005 Q2 | -5.29 Million USD | -13.31% |
| 2005 FY | -19.19 Million USD | -34.66% |
| 2005 Q3 | -5.68 Million USD | -7.35% |
| 2005 Q1 | -4.67 Million USD | -109.98% |
| 2005 Q4 | -3.54 Million USD | 37.55% |
| 2004 Q3 | -2.72 Million USD | 38.79% |
| 2004 Q4 | -2.22 Million USD | 18.32% |
| 2004 Q1 | -4.85 Million USD | 22.99% |
| 2004 Q2 | -4.45 Million USD | 8.4% |
| 2004 FY | -14.25 Million USD | 3.88% |
| 2003 Q2 | -6.91 Million USD | -733.13% |
| 2003 Q4 | -6.3 Million USD | -708.72% |
| 2003 FY | -14.83 Million USD | 37.59% |
| 2003 Q1 | -830 Thousand USD | 86.37% |
| 2003 Q3 | -780 Thousand USD | 88.72% |
| 2002 FY | -23.76 Million USD | 12.52% |
| 2002 Q1 | -6.4 Million USD | 20.63% |
| 2002 Q2 | -6.43 Million USD | -0.48% |
| 2002 Q3 | -4.83 Million USD | 24.9% |
| 2002 Q4 | -6.09 Million USD | -25.98% |
| 2001 Q3 | -6.99 Million USD | -19.21% |
| 2001 Q4 | -8.07 Million USD | -15.43% |
| 2001 Q2 | -5.86 Million USD | 6.05% |
| 2001 Q1 | -6.24 Million USD | 51.73% |
| 2001 FY | -27.17 Million USD | 42.99% |
| 2000 Q3 | -27.57 Million USD | -574.96% |
| 2000 FY | -47.65 Million USD | -78.49% |
| 2000 Q4 | -12.93 Million USD | 53.1% |
| 2000 Q2 | -4.08 Million USD | -33.42% |
| 2000 Q1 | -3.06 Million USD | -5.59% |
| 1999 FY | -26.7 Million USD | -206.9% |
| 1999 Q1 | -2.7 Million USD | -268.75% |
| 1999 Q2 | -5.9 Million USD | -118.52% |
| 1999 Q3 | -15.2 Million USD | -157.63% |
| 1999 Q4 | -2.9 Million USD | 80.92% |
| 1998 Q2 | -3.2 Million USD | 15.79% |
| 1998 Q4 | 1.6 Million USD | 147.06% |
| 1998 Q3 | -3.4 Million USD | -6.25% |
| 1998 Q1 | -3.8 Million USD | 9.52% |
| 1998 FY | -8.7 Million USD | 38.73% |
| 1997 Q3 | -2.8 Million USD | 26.32% |
| 1997 Q1 | -3.5 Million USD | -9.38% |
| 1997 FY | -14.2 Million USD | 45.38% |
| 1997 Q4 | -4.2 Million USD | -50.0% |
| 1997 Q2 | -3.8 Million USD | -8.57% |
| 1996 FY | -26 Million USD | -162.63% |
| 1996 Q4 | -3.2 Million USD | 8.57% |
| 1996 Q3 | -3.5 Million USD | 78.66% |
| 1996 Q1 | -2.9 Million USD | -7.41% |
| 1996 Q2 | -16.4 Million USD | -465.52% |
| 1995 Q3 | -2.2 Million USD | 8.33% |
| 1995 Q4 | -2.7 Million USD | -22.73% |
| 1995 FY | -9.9 Million USD | -17.86% |
| 1995 Q1 | -2.6 Million USD | -13.04% |
| 1995 Q2 | -2.4 Million USD | 7.69% |
| 1994 Q4 | -2.3 Million USD | -4.55% |
| 1994 FY | -8.4 Million USD | -64.71% |
| 1994 Q1 | -1.8 Million USD | -38.46% |
| 1994 Q2 | -2.1 Million USD | -16.67% |
| 1994 Q3 | -2.2 Million USD | -4.76% |
| 1993 Q4 | -1.3 Million USD | 0.0% |
| 1993 Q1 | -1.2 Million USD | 0.0% |
| 1993 FY | -5.1 Million USD | 0.0% |
| 1993 Q3 | -1.3 Million USD | 0.0% |
| 1993 Q2 | -1.3 Million USD | -8.33% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | -138.399% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -699.873% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | -41.433% |
| Azitra, Inc. | -11.28 Million USD | -511.896% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | -804.441% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | -835.469% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | -136.326% |
| CEL-SCI Corporation | -32.36 Million USD | -113.327% |
| iBio, Inc. | -24.9 Million USD | -177.211% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | -221.349% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | -249.19% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | -200.955% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -354.927% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | -616.234% |
| NanoViricides, Inc. | -8.29 Million USD | -732.455% |
| Oragenics, Inc. | -20.65 Million USD | -234.265% |
| BiomX Inc. | -26.16 Million USD | -163.843% |
| BiomX Inc. | -26.16 Million USD | -163.843% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 930.667% |
| Palatin Technologies, Inc. | -29.73 Million USD | -132.192% |
| Scorpius Holdings, Inc. | -45.21 Million USD | -52.696% |
| Theriva Biologics, Inc. | -18.34 Million USD | -276.288% |